About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Alembic Pharmaceuticals Ltd.
Change Company
BSE Code
533573
ISIN Demat
INE901L01018
Book Value
255.98
NSE Code
APLLTD
Dividend Yield %
1.04
Market Cap
207374.10
P/E
26.69
EPS
39.53
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
20-Dec-2024
Alembic Pharmaceuticals gets USFDA’s final approv...
11-Dec-2024
Alembic Pharmaceuticals completes ANVISA GMP audi...
11-Dec-2024
Alembic Pharmaceuticals informs about updates
04-Dec-2024
Alembic Pharma gets USFDA’s tentative nod for Olo...
02-Dec-2024
Alembic Pharmaceuticals informs about details of ...
25-Nov-2024
USFDA completes inspection at Alembic Pharmaceuti...
12-Nov-2024
Alembic Pharma gets USFDA’s final approval for Iv...
11-Nov-2024
Alembic Pharma gets final nod for Diltiazem Hydro...
11-Nov-2024
Alembic Pharmaceuticals informs about press rele...
23-Oct-2024
Alembic Pharmaceuticals informs about loss of sha...
21-Oct-2024
Alembic Pharma gets USFDA approval for Diltiazem ...
21-Oct-2024
Alembic Pharma soars on getting USFDA approval fo...
09-Oct-2024
USFDA completes inspection at Alembic Pharmaceuti...
09-Oct-2024
Alembic Pharmaceuticals informs about disclosure
04-Oct-2024
Alembic Pharmaceuticals gets final nod for Alcaft...
Page
1
of
4
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.